Form D · Biotechnology
Protogenix Inc.
Ithaca, NY · CIK 0002110349
Offering snapshot reported Feb 13, 2026 · SEC filing
- Reported sold
- $250K Offering amount: $4.2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 24, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 13, 2026 | Initial | $250,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-573570
Source: Form D, filed Feb 13, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric R Pettee | Director, Executive |
| Robert Poltrino | Director |
| Christopher Pj Wightman | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
237 Tower Rd Weill Hall 409
Ithaca, NY, 14853
Ithaca, NY, 14853